A detailed history of Elkhorn Partners Limited Partnership transactions in Moderna, Inc. stock. As of the latest transaction made, Elkhorn Partners Limited Partnership holds 2,200 shares of MRNA stock, worth $81,070. This represents 0.09% of its overall portfolio holdings.

Number of Shares
2,200
Holding current value
$81,070
% of portfolio
0.09%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$63.64 - $125.14 $140,008 - $275,308
2,200 New
2,200 $147,000
Q4 2023

Feb 13, 2024

SELL
$69.51 - $104.43 $43,791 - $65,790
-630 Reduced 53.39%
550 $55,000
Q3 2023

Nov 13, 2023

BUY
$96.41 - $126.61 $84,840 - $111,416
880 Added 293.33%
1,180 $122,000
Q2 2023

Aug 14, 2023

BUY
$118.5 - $160.53 $35,550 - $48,159
300 New
300 $36,000
Q2 2021

Aug 13, 2021

SELL
$129.91 - $234.98 $38,973 - $70,494
-300 Closed
0 $0
Q1 2021

May 11, 2021

BUY
$109.18 - $185.98 $32,754 - $55,794
300 New
300 $39,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Elkhorn Partners Limited Partnership Portfolio

Follow Elkhorn Partners Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Elkhorn Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Elkhorn Partners Limited Partnership with notifications on news.